How Birch Trees Contribute to Chaga's Chemistry

Chaga Bioactive Compounds

20-30% betulin in birch outer bark

Birch bark contains 20-30% betulin by weight. When Chaga parasitizes birch, it absorbs this betulin, converts some to betulinic acid, and (according to a 2019 RNA-Seq study) uses it as a signal to upregulate its own terpenoid biosynthesis genes.

Fradj et al., International Journal of Molecular Sciences, 2019

2 species

Betula pendula vs. pubescens produce measurably different Chaga compound profiles (Raal 2024)

0.19% w/w

inotodiol concentration in wild birch-grown Chaga, used as an authenticity threshold (Windsor 2025)

RNA-Seq

the genomic method that revealed birch betulin upregulates Chaga's own terpenoid-producing genes

Fradj et al., International Journal of Molecular Sciences, 2019

View as image ↗

Most Chaga content describes the relationship between birch trees and Chaga chemistry in one sentence: Chaga absorbs birch compounds. That framing, while partly accurate, misses something biochemically remarkable. A 2019 RNA-Seq study found that when Chaga is exposed to birch betulin, the fungus doesn't just passively absorb it. Chaga's own terpenoid biosynthesis genes are upregulated, meaning birch betulin actively signals Chaga to produce more of its own bioactive compounds.^[1]

Understanding how birch trees contribute to Chaga's chemistry therefore requires separating two distinct processes: what Chaga takes from birch, and what birch triggers Chaga to make. This article covers both, as well as the 2024 evidence showing that birch species specifically, not just birch in general, determines the compound profile and potency of the resulting Chaga. For a broader introduction to bioactive compounds in medicinal mushrooms, see what beta-glucans are and why they matter in medicinal mushrooms.

The RNA-Seq Discovery: Birch Betulin as a Chemical Signal, Not Just a Source

Birch betulin has been known to appear in Chaga extracts for decades. The conventional explanation was passive absorption: Chaga grows in birch wood, takes up compounds from its host, and those compounds accumulate in the fungal tissue.

Fradj and colleagues tested a different hypothesis.^[1] Using RNA sequencing (a technique that reads which genes a cell is actively using at a given moment), they cultured Chaga with and without birch bark as a source of betulin, then compared the gene expression profiles. The result: Chaga cultured with birch bark showed upregulation of multiple genes in the terpenoid biosynthesis pathway.

To understand why this matters, consider the distinction between two scenarios. In the passive absorption scenario, birch betulin enters Chaga like water enters a sponge: the fungus takes it up, it accumulates, and it appears in the final product. Chaga's own biochemistry is a bystander.

In the signaling scenario revealed by the RNA-Seq data, birch betulin functions more like a trigger. When Chaga detects betulin, it switches on genes for making its own triterpenoid compounds. Betulin is not just raw material; it is a molecular message that tells Chaga to activate a production program.

The practical implication is significant for understanding Chaga quality. A Chaga sample grown without birch contact, such as a laboratory-cultivated mycelium or a Chaga growing on a non-birch host, does not receive this signal. Its terpenoid biosynthesis genes may not be activated to the same degree. This provides a mechanistic explanation for why wild birch-grown Chaga and birch-contact cultivation consistently produce different compound profiles than laboratory methods that bypass the host relationship.

What Chaga Takes from Birch: The Betulin-to-Betulinic-Acid Conversion

Birch outer bark is one of the richest known sources of betulin in the plant kingdom, containing 20-30% betulin by dry weight. Betulin is a pentacyclic triterpene alcohol that gives birch bark its characteristic white color.

Betulinic acid is the carboxylated form of betulin: a version with an additional oxygen group that substantially increases its solubility and pharmacological activity. When Chaga grows on birch, it absorbs betulin from the bark and converts some of it enzymatically to betulinic acid. A comprehensive chemical characterization confirmed that both betulin and betulinic acid are present in Chaga, along with inotodiol and melanin as distinct compound classes.^[2]

Betulinic acid is the pharmacologically active form that has been studied for anti-cancer, antiviral, and anti-inflammatory properties. Betulin itself has relatively poor oral bioavailability and weaker receptor binding. The conversion step that Chaga performs, from betulin to betulinic acid, increases both the accessibility and the potency of the compound. This is relevant for comparing Chaga to birch bark extracts: birch bark supplements may have high betulin content but lower betulinic acid than Chaga, and it is the acid form that has been most extensively studied for pharmacological effects.

For the full research on what betulinic acid does at the molecular level, including the apoptosis mechanism in cancer cells and antiviral evidence, see betulinic acid from Chaga: anti-cancer and antiviral research.

What Chaga Makes Itself: Inotodiol and the Lanostane Triterpenoids

Not all of Chaga's bioactive triterpenoids come from birch. Inotodiol, a lanostane triterpenoid found only in Inonotus obliquus, is synthesized by Chaga's own biosynthetic machinery, with betulin apparently serving as a triggering signal rather than a direct chemical precursor.

Nakata and colleagues first characterized inotodiol and two related compounds (inonotsuoxides A and B) and demonstrated that inotodiol showed significant in vivo anti-tumor promoting activity in a two-stage mouse skin carcinogenesis model.^[3] The DMBA/TPA model used in that study is a well-established system for assessing anti-tumor promoting activity, where one chemical (DMBA) initiates cancer and a second (TPA) promotes its development. Inotodiol interfered with the promotion stage.

A 2020 analysis quantified four highly active triterpenoids in Chaga: inotodiol, trametenolic acid, 3-hydroxy-lanosta-8,24-dien-21-al, and betulin.^[4] All four were able to decrease breast cancer cell viability and arrest the cell cycle at the G0/G1 phase, a resting state that prevents cell division. The mechanism involved reduction of cyclin D1 and CDK4, two proteins that normally push cells from G0/G1 into active division. By downregulating these proteins, the triterpenoids caused the cancer cells to stop dividing.

This profile of four active triterpenoids reflects Chaga's compound architecture as a product of both birch-derived and self-synthesized chemistry. Betulin appears on the list as a compound absorbed from birch, while inotodiol and trametenolic acid are Chaga-synthesized lanostanes whose production is partly driven by the birch betulin signal.

For the lanostane triterpenoid class context across medicinal mushrooms, see lanostane triterpenes in medicinal mushrooms. For a comparison with reishi's triterpenoid profile, see ganoderic acids from reishi: a complete guide.

The 2024 Evidence: Not All Birch Is the Same

The conventional assumption in Chaga research is that growing on birch is the important factor, with the specific birch species treated as irrelevant. A 2024 study challenged this.

Raal and colleagues collected Chaga growing on Betula pendula (silver birch) and Betula pubescens (downy birch), two closely related species that share overlapping habitats across northern Europe and Russia, then compared the chemical content and cytotoxic activity of extracts from each.^[8] The results showed measurably different chemical profiles between the two host species. The cytotoxic activity of the extracts against tested cancer cell lines also differed.

This finding matters for two reasons. First, it confirms that the birch-Chaga relationship is not a simple passive transfer where any birch tree produces equivalent chemistry in the Chaga growing on it. The specific biochemistry of the host tree influences what the fungus produces. Second, it introduces a sourcing variable that supplement manufacturers rarely disclose: whether Chaga was harvested from silver birch or downy birch (or a different Betula species entirely) may affect the compound content of the product.

Betula pendula and pubescens have different bark compositions. Silver birch typically has higher betulin content in its outer bark. If birch betulin drives Chaga's terpenoid gene expression, as the Fradj 2019 RNA-Seq data indicates, then higher host betulin content should produce stronger induction of Chaga's own triterpenoid production. The Raal 2024 cytotoxicity differences are consistent with this model, though a direct mechanistic link between host betulin levels and Chaga terpenoid yield has not yet been quantified in a controlled experiment.

Wild vs. Cultivated Chaga: What the Quality Data Shows

The question of wild versus cultivated Chaga is partly a question of whether the birch-betulin signaling mechanism has been operative during the fungus's development.

A 2025 comparative analysis of commercial Chaga supplement products measured inotodiol content across different product types using standardized analytical methods.^[9] Wild Chaga canker from northern birch forests contained inotodiol at 0.19% w/w. This figure was compared against an authentication threshold of 0.1165% w/w: the minimum inotodiol concentration that distinguishes genuine wild Chaga from inferior products or potential adulterants.

The 2025 study found that commercial supplement products varied considerably in their inotodiol content. Products that met or exceeded the authentication threshold were more consistently associated with wild-harvested, birch-grown material. Products falling below the threshold included cultivated substrates and some products of uncertain provenance.

A 2021 comprehensive review covering Chaga from its Siberian folk medicine origins through modern pharmacological research confirmed that the absence of human clinical trials remains the central gap in Chaga evidence, while noting that the preclinical evidence across betulinic acid, inotodiol, and melanin is substantial and mechanistically coherent.^[5] A 2023 review reinforced this assessment, confirming the three-compound framework and updating the evidence quality assessment.^[6] The most recent 2024 review added updated coverage of anti-inflammatory, anti-diabetic, and hepatoprotective evidence alongside the anti-cancer data.^[7]

The Third Compound Layer: Birch Polyphenols and Chaga Melanin

The birch-Chaga relationship extends beyond triterpenoids to include melanin production.

Chaga's characteristic dark outer surface is one of the richest natural sources of a specific melanin type called allomelanin, a melanin formed from phenolic compounds rather than the DOPA-based pathway that produces human skin melanin. A significant fraction of the phenolic precursors for Chaga's allomelanin comes from birch tissue, including birch polyphenols that Chaga incorporates into its melanin synthesis.

This creates a three-layer bioactive framework in birch-grown Chaga: betulinic acid (derived directly from birch betulin), lanostane triterpenoids including inotodiol (synthesized by Chaga but signaled by betulin), and allomelanin (built partly from birch phenolic compounds). All three layers are present in wild, birch-grown Chaga at their highest concentrations and are diminished or altered in cultivated, non-birch, or laboratory-grown preparations.

For the complete picture of Chaga's melanin chemistry, including the bifidogenic gut microbiome properties discovered in 2019, see chaga melanin: the unique pigment with health benefits and chaga melanin vs. human melanin: structure, function, and photoprotection. For the pharmacology of Chaga's triterpenoids as a compound class, see mushroom triterpenes: the bitter compounds with powerful effects.

What This Means for Supplement Quality

The birch-Chaga chemical relationship has direct implications for what to look for in Chaga products.

The RNA-Seq signaling evidence (Fradj 2019) and the host-species variation data (Raal 2024) together support a view of Chaga quality that goes beyond "does this product contain betulinic acid?" The more precise question is: was this Chaga grown on birch in the conditions that activate its full terpenoid biosynthesis program?

Products made from wild-harvested Chaga from northern birch forests, verified to contain inotodiol at or above the 0.1165% w/w authentication threshold, represent the compound profile that the preclinical evidence is based on. Products made from laboratory-cultivated mycelium or from Chaga grown on non-birch substrates may have similar names but different biochemistry.

None of this constitutes clinical trial evidence for any specific health effect; Chaga has not been tested in controlled human trials. But when evaluating preclinical research, the compound profile of the tested material matters. Most Chaga studies have used wild birch-grown material. Extrapolating those findings to laboratory-cultivated products requires an assumption of compound equivalence that the Raal 2024 and Windsor 2025 data suggest is not warranted.

For a complete look at inotodiol specifically, including its immunomodulatory mechanism and anti-inflammatory profile, see inotodiol: Chaga's other important bioactive compound.

The Bottom Line

Birch trees contribute to Chaga's chemistry through two mechanisms: passive transfer of betulin (which Chaga converts to the more bioactive betulinic acid) and active signaling (birch betulin upregulates Chaga's own terpenoid biosynthesis genes, a finding from Fradj et al.'s 2019 RNA-Seq experiment). The specific birch species matters: Chaga on Betula pendula vs. pubescens shows different chemical profiles and different cytotoxic activities. Wild birch-grown Chaga consistently contains more inotodiol than cultivated preparations, with 0.19% w/w documented in wild cankers against a 0.1165% authentication threshold. Three bioactive layers result from this relationship: betulinic acid (birch-derived), inotodiol and lanostane triterpenoids (Chaga-synthesized but betulin-signaled), and allomelanin (incorporating birch polyphenols).

Frequently Asked Questions

Why does chaga only grow on birch trees?

Chaga is technically a parasite that grows on several Betula species and occasionally on other hardwoods, but its most prized and pharmacologically studied form is birch-grown. Birch trees are ideal hosts because their bark is exceptionally rich in betulin (20-30% of outer bark dry weight), which Chaga uses as both a raw material and a biosynthetic signal. Chaga can grow on other trees, but without betulin exposure, the RNA-Seq evidence suggests its terpenoid biosynthesis genes are not activated in the same way, producing a different and typically less potent compound profile.

Does chaga from different trees have different properties?

Yes. A 2024 study directly compared Chaga growing on Betula pendula (silver birch) and Betula pubescens (downy birch), two closely related species with overlapping ranges in northern Europe. The Chaga from the two host species showed measurably different chemical profiles and different cytotoxic activities against tested cancer cell lines. Chaga growing on non-birch trees shows even more dramatic differences: without betulin in the host bark, the fungus cannot perform the betulin-to-betulinic-acid conversion and may not receive the terpenoid biosynthesis signal that birch betulin provides.

How does the birch tree affect chaga's health benefits?

In two distinct ways. First, birch outer bark provides betulin, which Chaga converts to betulinic acid. This direct compound transfer makes Chaga one of the highest dietary sources of betulinic acid, a compound with documented anti-cancer, antiviral, and anti-inflammatory properties in preclinical studies. Second, birch betulin serves as a molecular signal that activates Chaga's own terpenoid biosynthesis genes, increasing production of compounds like inotodiol and trametenolic acid that Chaga synthesizes independently. Both mechanisms require a living birch host, which is why wild-harvested birch Chaga has a different bioactive profile from laboratory-cultivated preparations.

Does wild chaga have more betulinic acid than cultivated chaga?

Wild birch-grown Chaga generally contains higher and more consistent concentrations of birch-derived compounds including betulinic acid and betulin than laboratory-cultivated mycelium, because cultivated preparations often lack the birch host relationship that provides the betulin source and biosynthetic signal. A 2025 comparative analysis found wild Chaga canker contained inotodiol at 0.19% w/w, exceeding the 0.1165% authentication threshold. Commercial supplement products varied considerably, with products below this threshold associated with non-wild-harvested material.

What happens to chaga's properties if it grows on non-birch trees?

Chaga growing on non-birch hosts lacks access to betulin and therefore cannot perform the betulin-to-betulinic-acid conversion, and does not receive the betulin signal that upregulates terpenoid biosynthesis genes. The resulting compound profile is different: lower or absent betulinic acid, potentially lower lanostane triterpenoid content including inotodiol, and a different melanin profile. The preclinical pharmacological evidence for Chaga is based almost entirely on birch-grown material, so extrapolating research findings to non-birch Chaga products requires assuming compound equivalence that the 2024 host-species comparison study does not support.

Sources & References

1. 1RTHM-01057·Fradj, Narimene et al. (2019). “RNA-Seq de Novo Assembly and Differential Transcriptome Analysis of Chaga (Inonotus obliquus) Cultured with Different Betulin Sources and the Regulation of Genes Involved in Terpenoid Biosynthesis..” International journal of molecular sciences.Study breakdown →PubMed →↩
2. 2RTHM-00373·Glamočlija, Jasmina et al. (2015). “Chemical characterization and biological activity of Chaga (Inonotus obliquus), a medicinal "mushroom"..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
3. 3RTHM-00225·Nakata, Tomoko et al. (2007). “Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus..” Bioorganic & medicinal chemistry.Study breakdown →PubMed →↩
4. 4RTHM-01218·Kim, Jaecheol et al. (2020). “Composition of Triterpenoids in Inonotus obliquus and Their Anti-Proliferative Activity on Cancer Cell Lines..” Molecules (Basel.Study breakdown →PubMed →↩
5. 5RTHM-00722·Szychowski, Konrad A et al. (2021). “Inonotus obliquus - from folk medicine to clinical use..” Journal of traditional and complementary medicine.Study breakdown →PubMed →↩
6. 6RTHM-01694·Fordjour, Eric et al. (2023). “Chaga mushroom: a super-fungus with countless facets and untapped potential..” Frontiers in pharmacology.Study breakdown →PubMed →↩
7. 7RTHM-01886·Ern, Phoebe Tee Yon et al. (2024). “Chaga Therapeutic Properties: What This 2024 Review Actually Shows.” Mycology.Study breakdown →PubMed →↩
8. 8RTHM-01972·Raal, Ain et al. (2024). “Chemical Content and Cytotoxic Activity on Various Cancer Cell Lines of Chaga (Inonotus obliquus) Growing on Betula pendula and Betula pubescens..” Pharmaceuticals (Basel.Study breakdown →PubMed →↩
9. 9RTHM-02209·Windsor, Coleton et al. (2025). “What This 2025 Chaga Supplement Authentication Study Actually Found.” International journal of molecular sciences.Study breakdown →PubMed →↩